与阿特佐利祖马布-贝瓦齐祖马布的下降:一个案例系列
Anand V Kulkarni1, Parthasarathy Kumaraswamy2, Balachandran Menon2
1Department of Hepatology, AIG Hospitals, Hyderabad, India.
Journal of liver cancer
|May 27, 2024
概括
阿特佐利祖马布-贝瓦齐祖马布治疗可以帮助选择肝细胞癌患者进行肝移植. 一些患者在治疗后获得了完整的病理反应,使得像LT这样的治疗疗法成为可能.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 医学瘤学 医学瘤学
- 移植手术 移植手术
背景情况:
- 肝细胞癌 (HCC) 通常在晚期呈现,限制治疗选择.
- 局部治疗 (LRT) 是用于降低肝移植 (LT) 无法切除的HCC的标准.
- 阿特佐利祖马布-贝瓦西祖马布 (atezo-bev) 对降低HCC的疗效尚不清楚.
研究的目的:
- 评估阿特佐利祖马布-贝瓦齐祖马布 (atezo-bev) 在降低切除不了的肝细胞癌 (HCC) 的作用和结果.
- 评估治疗疗法的可行性,包括肝移植 (LT),在阿泰佐-贝夫治疗后.
主要方法:
- 从2020年11月到2023年8月接受atezo-bev的115名患者的回顾性单中心研究.
- 包括被认为要进行切除/LT的患者在与阿泰佐-贝夫降低后,有或没有先前的LRT.
- 评估的应答率,符合LT的资格,以及治愈治疗后的结果.
主要成果:
- 10.4%的患者 (12/115) 实现了客观反应,并且有资格接受LT.
- 六名患者接受了治愈疗法:四名活体供体LT,一名已故供体LT和一名切除.
- 所有接受LT或切除的患者都获得了完整的病理反应;移植后没有观察到HCC复发或移植拒绝.
结论:
- 阿特佐利祖马布-贝瓦西祖马布治疗可以促进选择的HCC患者的衰退.
- 在经过阿泰佐-贝夫治疗的精心挑选的患者中,可以进行手术治疗,包括LT.
- 完整的病理反应是常见的,支持治疗干预的潜力.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...